Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site: DMID 21-0012 Mix and Match

实施疫苗和治疗评估单位 (VTEU) 临床站点:DMID 21-0012 混合搭配

基本信息

  • 批准号:
    10424839
  • 负责人:
  • 金额:
    $ 112.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-08-10 至 2025-11-30
  • 项目状态:
    未结题

项目摘要

Summary/Abstract The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), causative agent of the coronavirus disease of 2019 (COVID-19) which was designated as a pandemic respiratory illness (WHO - 2020), has infected over 172 million people worldwide and resulted in over 3.7 million deaths, including > 596,000 in the United States (June 3, 2021, WHO; www.who.int). Multiple Phase 3 efficacy trials of SARS-CoV-2 vaccine constructs are underway or in long-term follow-up in the U.S, and these studies have supported 3 Emergency Use Authorizations (EUAs) for COVID vaccines. However, logistical and manufacturing obstacles are limiting the number of vaccines available at any one time. Further, the emergence of variant strains has raised concerns about the breadth of immunity and protection achieved by the current vaccines. WHO SAGE and CDC ACIP have identified the safety and immunogenicity of mixed schedules as a critical and immediate research priority to inform policy on the use of mixed schedules. Knowledge of the safety, tolerability, and immunogenicity of a delayed boost vaccine incorporating a heterologous platform or variant spike lineage administered following EUA prime dosing regimens may greatly stretch the ability to immunize against SARS-CoV-2 at a population level, induce immunity to variant circulating strains and improve upon the breadth and durability of protection. The heterologous boost strategy will also provide an opportunity to thoroughly evaluate innate, cellular, and humoral immune responses elicited from the multiple prime boost combinations using very similar immunogens, utilizing mRNA, adenovirus- vectored, and protein- based platforms. As new immunogens are manufactured to closely match emerging variants, these foundational data will be key to the evaluation of future variant and heterologous prime- boost strategies. This phase 1/2 clinical trial will evaluate the safety and immunogenicity of different heterologous delayed doses (boosts) in those who received an EUA vaccine (either prior to participation in this trial, or as part of this trial).
总结/摘要 严重急性呼吸道综合征冠状病毒2(SARS-CoV-2),冠状病毒的病原体 被指定为大流行性呼吸道疾病(WHO - 2020)的2019年疾病(COVID-19), 全世界感染了1.72亿多人,导致370多万人死亡,其中包括超过596,000人, 美国(2021年6月3日,WHO; www.who.int)。SARS-CoV-2疫苗的多项3期有效性试验 在美国,这些结构正在进行或处于长期随访中,这些研究支持了3种紧急情况, COVID疫苗的使用授权(EUA)。然而,物流和制造障碍是有限的 在任何时候都可以获得的疫苗数量。此外,变异株的出现提高了 对目前疫苗所实现的免疫和保护广度的关切。WHO SAGE和 CDC ACIP已经确定了混合方案的安全性和免疫原性, 研究优先事项,为使用混合时间表的政策提供信息。 了解包含以下物质的延迟加强疫苗的安全性、耐受性和免疫原性: 在EUA初始给药方案后施用的异源平台或变体刺突谱系可 极大地扩展了在群体水平上对SARS-CoV-2免疫的能力,诱导对变异株的免疫, 循环应变和改善的广度和持久性的保护。异源加强策略 还将提供彻底评估先天、细胞和体液免疫反应的机会 使用非常相似的免疫原,利用mRNA, 腺病毒载体和基于蛋白质的平台。随着新的免疫原被制造出来, 新出现的变异,这些基础数据将是评估未来变异和异源的关键。 prime-boost策略。这项1/2期临床试验将评估不同的免疫抑制剂的安全性和免疫原性。 在接受EUA疫苗的受试者中,异源延迟剂量(加强)(在参与 或作为本试验的一部分)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Karen L. Kotloff其他文献

Systems approach to define humoral correlates of immunity to emShigella/em
系统方法来定义对志贺氏菌的免疫体液相关性
  • DOI:
    10.1016/j.celrep.2022.111216
  • 发表时间:
    2022-08-16
  • 期刊:
  • 影响因子:
    6.900
  • 作者:
    Biana Bernshtein;Esther Ndungo;Deniz Cizmeci;Peng Xu;Pavol Kováč;Meagan Kelly;Dilara Islam;Edward T. Ryan;Karen L. Kotloff;Marcela F. Pasetti;Galit Alter
  • 通讯作者:
    Galit Alter
Predictive modelling of linear growth faltering among pediatric patients with Diarrhea in Rural Western Kenya: an explainable machine learning approach
  • DOI:
    10.1186/s12911-024-02779-7
  • 发表时间:
    2024-12-02
  • 期刊:
  • 影响因子:
    3.800
  • 作者:
    Billy Ogwel;Vincent H. Mzazi;Alex O. Awuor;Caleb Okonji;Raphael O. Anyango;Caren Oreso;John B. Ochieng;Stephen Munga;Dilruba Nasrin;Kirkby D. Tickell;Patricia B. Pavlinac;Karen L. Kotloff;Richard Omore
  • 通讯作者:
    Richard Omore
Characterization of emShigella flexneri/em serotype 6 strains from geographically diverse low- and middle-income countries
来自不同地理区域的中低收入国家的 em 弗氏志贺菌 6 型菌株的特征描述
  • DOI:
    10.1128/mbio.02210-24
  • 发表时间:
    2024-11-29
  • 期刊:
  • 影响因子:
    4.700
  • 作者:
    Caitlin E. Gabor;Charlotte E. Chong;Jose M. Lemme-Dumit;Tracy H. Hazen;Kate S. Baker;Karen L. Kotloff;Irene N. Kasumba;Sharon M. Tennant;Henry Badji;M. Jahangir Hossain;Richard Omore;Benjamin Ochieng;Alex O. Awuor;Billy Ogwel;Jane Juma;Eileen M. Barry;David A. Rasko
  • 通讯作者:
    David A. Rasko
Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator
随机、安慰剂对照、双盲 2 期试验,比较单一标准剂量与高剂量 CVD 103-HgR 减毒口服霍乱活疫苗(使用 Shanchol 灭活口服疫苗作为开放标签免疫学)的反应原性和免疫原性
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    S. Sow;M. Tapia;Wilbur H. Chen;F. Haidara;Karen L. Kotloff;Marcela F. Pasetti;William C. Blackwelder;A. Traoré;Boubou Tamboura;Moussa Doumbia;F. Diallo;F. Coulibaly;Uma Onwuchekwa;Mamoudou Kodio;S. Tennant;M. Reymann;Diana F. Lam;Marc Gurwith;Michael D. Lock;Thomas Yonker;Jonathan Smith;Jakub K. Simon;Myron M Levine
  • 通讯作者:
    Myron M Levine
Epidemiology of human metapneumovirus among children with severe or very severe pneumonia in high pneumonia burden settings: the Pneumonia Etiology Research for Child Health (PERCH) study experience
高肺炎负担环境中患有严重或极严重肺炎儿童中人偏肺病毒的流行病学:儿童健康肺炎病因学研究(PERCH)的经验
  • DOI:
    10.1016/j.cmi.2024.10.023
  • 发表时间:
    2025-03-01
  • 期刊:
  • 影响因子:
    8.500
  • 作者:
    Ryo Miyakawa;Haijun Zhang;W. Abdullah Brooks;Christine Prosperi;Henry C. Baggett;Daniel R. Feikin;Laura L. Hammitt;Stephen R.C. Howie;Karen L. Kotloff;Orin S. Levine;Shabir A. Madhi;David R. Murdoch;Katherine L. O'Brien;J. Anthony G. Scott;Donald M. Thea;Martin Antonio;Juliet O. Awori;Charatdao Bunthi;Amanda J. Driscoll;Bernard Ebruke;Maria Deloria Knoll
  • 通讯作者:
    Maria Deloria Knoll

Karen L. Kotloff的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Karen L. Kotloff', 18)}}的其他基金

Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
实施疫苗和治疗评估单位 (VTEU) 临床基地
  • 批准号:
    10580873
  • 财政年份:
    2022
  • 资助金额:
    $ 112.15万
  • 项目类别:
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site: COVPN 3004 Boost
实施疫苗和治疗评估单位 (VTEU) 临床站点:COVPN 3004 Boost
  • 批准号:
    10639869
  • 财政年份:
    2022
  • 资助金额:
    $ 112.15万
  • 项目类别:
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
实施疫苗和治疗评估单位 (VTEU) 临床基地
  • 批准号:
    10493529
  • 财政年份:
    2021
  • 资助金额:
    $ 112.15万
  • 项目类别:
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
实施疫苗和治疗评估单位 (VTEU) 临床基地
  • 批准号:
    10395066
  • 财政年份:
    2021
  • 资助金额:
    $ 112.15万
  • 项目类别:
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
实施疫苗和治疗评估单位 (VTEU) 临床基地
  • 批准号:
    10659359
  • 财政年份:
    2021
  • 资助金额:
    $ 112.15万
  • 项目类别:
VTEU Supplement
VTEU 补充
  • 批准号:
    10303002
  • 财政年份:
    2021
  • 资助金额:
    $ 112.15万
  • 项目类别:
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site:21-0011
实施疫苗和治疗评估单位 (VTEU) 临床站点:21-0011
  • 批准号:
    10414457
  • 财政年份:
    2021
  • 资助金额:
    $ 112.15万
  • 项目类别:
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site: CoVPN 3004
实施疫苗和治疗评估单位 (VTEU) 临床站点:CoVPN 3004
  • 批准号:
    10410208
  • 财政年份:
    2021
  • 资助金额:
    $ 112.15万
  • 项目类别:
Vaccine Treatment Evaluation Units(VTEU) mRNA-1273-P204 Moderna Pediatric
疫苗治疗评估单位 (VTEU) mRNA-1273-P204 Moderna 儿科
  • 批准号:
    10397325
  • 财政年份:
    2021
  • 资助金额:
    $ 112.15万
  • 项目类别:
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
实施疫苗和治疗评估单位 (VTEU) 临床基地
  • 批准号:
    10659362
  • 财政年份:
    2021
  • 资助金额:
    $ 112.15万
  • 项目类别:

相似海外基金

Clinical application of boron-conjugated adenovirus vector for neutron capture therapy
硼缀合腺病毒载体中子捕获治疗的临床应用
  • 批准号:
    19K09482
  • 财政年份:
    2019
  • 资助金额:
    $ 112.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Vascular-targeted gene therapy to block proliferation of smooth muscle cells using a novel adenovirus vector
使用新型腺病毒载体进行血管靶向基因治疗以阻止平滑肌细胞增殖
  • 批准号:
    2273599
  • 财政年份:
    2019
  • 资助金额:
    $ 112.15万
  • 项目类别:
    Studentship
Gene therapy for diabetes mellitus based on the suppression of lipotoxicity using an improved adenovirus vector
使用改进的腺病毒载体抑制脂毒性的糖尿病基因治疗
  • 批准号:
    18K14964
  • 财政年份:
    2018
  • 资助金额:
    $ 112.15万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanisms of induction of mucosal immunity by adenovirus vector vaccine
腺病毒载体疫苗诱导粘膜免疫的机制
  • 批准号:
    16K18873
  • 财政年份:
    2016
  • 资助金额:
    $ 112.15万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Hemophilia B Gene Therapy via CRISPR/Cas9-Targeted Integration of the Factor IX Gene using Adenovirus Vector Delivery
使用腺病毒载体递送通过 CRISPR/Cas9 靶向整合因子 IX 基因进行 B 型血友病基因治疗
  • 批准号:
    9193681
  • 财政年份:
    2016
  • 资助金额:
    $ 112.15万
  • 项目类别:
Gene therapy for diabetes mellitus and gene function analysis using a novel adenovirus vector
使用新型腺病毒载体进行糖尿病基因治疗和基因功能分析
  • 批准号:
    15K18939
  • 财政年份:
    2015
  • 资助金额:
    $ 112.15万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Innate immue response through glycolipids by adenovirus-vector
腺病毒载体通过糖脂产生先天免疫反应
  • 批准号:
    26450450
  • 财政年份:
    2014
  • 资助金额:
    $ 112.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of targeting adenovirus vector as boron carrier for boron neutron capture therapy
开发靶向腺病毒载体作为硼中子捕获疗法的硼载体
  • 批准号:
    26462183
  • 财政年份:
    2014
  • 资助金额:
    $ 112.15万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel method for highly efficient gene targeting by adenovirus vector on human naive pluripotent stem cells
开发一种通过腺病毒载体高效基因靶向人类幼稚多能干细胞的新方法
  • 批准号:
    26893253
  • 财政年份:
    2014
  • 资助金额:
    $ 112.15万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Development of adenovirus vector lacking VA RNA genes for efficient microRNA expression
开发缺乏 VA RNA 基因的腺病毒载体以实现有效的 microRNA 表达
  • 批准号:
    24701021
  • 财政年份:
    2012
  • 资助金额:
    $ 112.15万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了